ERBB2 and neoplasm: In the HER2− tumoroid in model 3, 50% killing was reached after ∼24 h, lagging ∼12 h behind the HER2+ tumor without accumulation of T‐cells in the HER− tumor (Figure 5A,C,D; Figure S4).